Utilize este identificador para referenciar este registo: https://hdl.handle.net/10316/11856
Campo DCValorIdioma
dc.contributor.authorCustódio, Sofia-
dc.contributor.authorSaleiro, Sofia-
dc.contributor.authorDias, Margarida-
dc.contributor.authorFreire-de-Oliveira, Carlos-
dc.date.accessioned2009-10-29T09:10:02Z-
dc.date.available2009-10-29T09:10:02Z-
dc.date.issued2009-
dc.identifier.citationActa Obstétrica e Ginecológica Portuguesa. 3:1 (2009) 17-23en_US
dc.identifier.issn1646-5830-
dc.identifier.urihttps://hdl.handle.net/10316/11856-
dc.description.abstractIntroduction: Breast conserving therapy involves conservative surgery – excision of the tumor mass with negative surgical margins – followed by post-operative radiation therapy. The objective of this study was to assess the clinical results of breast conserving therapy in invasive cancer. Study design: Retrospective observational study. Material and Methods: Analysis of 231 patients with invasive breast cancer treated by conservative surgery in a tertiary care University Hospital over 11 years. Results: Average age at time of diagnosis was 55.2 years (23-87). Most patients (64.5%) were post-menopausal. Almost all patients presented with a suspicious nodule at radiologic examination (61.5%). No palpable lesions were found in 40.7% of patients. Clinical stage I was the most prevalent (82.7%) and most patients were biopsed guided by radiologic methods. The majority of patients (79.2%) was treated with lumpectomy /quadrantectomy and axillary lymph node excision. The most frequent histologic type was invasive ductal carcinoma, diagnosed in 69.2% of patients. In 73.6% of cases there was no evidence of lymph node metastases. Estrogen receptors were positive in 68.8% and CerbB2 was positive in 37.2%. Surgical margins were negative in 92.2%. Adjuvant therapy consisted of radiotherapy in 95%, hormonal therapy in 69.7% and chemotherapy in 48%, either alone or in association. Average time of follow-up was 66.6 months. During this period, 11 patients had local recurrence and 16 had distant metastases. Overall survival was 93.5% at 140 months and disease-free survival was 71.3% at 140 months. Conclusion: Conservative treatment appears to be a viable therapeutic option for invasive stage I and II breast cancer.en_US
dc.language.isoporen_US
dc.publisherFederação das Sociedades Portuguesas de Obstetrícia e Ginecologiaen_US
dc.rightsopenAccessen_US
dc.titleTratamento conservador do cancro da mama invasivo - avaliação de 11 anosen_US
dc.title.alternativeBreast conserving therapy in invasive breast cancer - 11 years of follow-upen_US
dc.typearticleen_US
item.fulltextCom Texto completo-
item.grantfulltextopen-
item.languageiso639-1pt-
item.cerifentitytypePublications-
item.openairetypearticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Aparece nas coleções:FMUC Medicina - Artigos em Revistas Nacionais
Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato
Tratamento conservador do cancro da mama invasivo.pdf330.46 kBAdobe PDFVer/Abrir
Mostrar registo em formato simples

Visualizações de página

385
Visto em 24/set/2024

Downloads 50

400
Visto em 24/set/2024

Google ScholarTM

Verificar


Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.